Use of Biologic Therapies With Different Mechanisms of Action (MOA) in the First-line (1L) Treatment of Crohn's Disease (CD) in the US

被引：0
|
作者：
Huang, Zhongwen [1 ]
Ba, Yi [1 ]
Kamble, Pravin [1 ]
Wang, Song [1 ]
机构：
[1] Takeda, Cambridge, MA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2021年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S917
引用
收藏
页码：S433 / S433
页数：1
相关论文
共 50 条
  • [1] Use of biologic therapies with different mechanisms of action (MOA) in the first-line (1L) treatment of Crohn's Disease (CD) in the US
    Huang, Z.
    Ba, Y.
    Kamble, P.
    Wang, S.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S084 - S084
  • [2] First-Line Treatment for Children and Adolescents With Crohn's Disease
    Leiz, Maren
    Moon, Kilson
    Tischler, Luisa
    de Laffolie, Jan
    van den Berg, Neeltje
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2023, 120 (14): : 251 - 252
  • [3] Different rate of transmural remission between first and second line of biologic treatment in Crohn's disease
    De Sire, R.
    Rispo, A.
    Caiazzo, A.
    Testa, A.
    Nardone, O. M.
    Guarino, A. D.
    Olmo, O.
    Calabrese, G.
    Fierro, G.
    Toro, B.
    Cantisani, N. M.
    Ferrante, M.
    La Mantia, A.
    D'Alessandro, E.
    Castiglione, F.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 520 - 520
  • [4] The Impact of Treatment Switch Among Prevalent Patients With Crohn's Disease Treated With a First-Line Biologic: A US Retrospective Claims Database Study
    Gagnon-Sanschagrin, Patrick
    Sanon, Myrlene
    Davidson, Mikhail
    Guerin, Annie
    Willey, Cynthia
    Kachroo, Sumesh
    Hoops, Timothy
    Naessens, Dominik
    Cloutier, Martin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10) : S592 - S592
  • [5] The economic impact of suboptimal treatment and treatment switch among patients with Crohn's disease treated with a first-line biologic - A US retrospective claims database study
    Gagnon-Sanschagrin, Patrick
    Sanon, Myrlene
    Davidson, Mikhail
    Willey, Cynthia
    Kachroo, Sumesh
    Hoops, Timothy
    Naessens, Dominik
    Guerin, Annie
    Cloutier, Martin
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 931 - 940
  • [6] Real-world safety of first-line (1L) therapies for locally advanced or metastatic urothelial cancer (la/mUC) in the US.
    Nizam, Amanda
    Kearney, Mairead
    Morris, Valerie A.
    Mahmoudpour, Seyed Hamidreza
    Lobo, Carroline
    Hoffman, Jason
    Iliev, Ilian
    Yerram, Prakirthi
    Guinter, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [7] Patterns and predictors of first-line (1L) taxane use in US patients with metastatic triple-negative breast cancer (mTNBC)
    O'Shaughnessy, J.
    Emens, L. A.
    Chui, S.
    Russell, K.
    Lin, S. -W.
    Avile, C. Flores
    Luhn, P.
    Schneeweiss, A.
    ANNALS OF ONCOLOGY, 2019, 30 : 131 - 131
  • [8] Adalimumab as first-line anti-TNF treatment in pediatric Crohn's disease
    Martin-de-Carpi, J.
    Navas-Lopez, V. M.
    Navalon-Rubio, M.
    Llerena-Santa-Cruz, E.
    Gil-Ortega, D.
    Varea-Calderon, V.
    Sierra-Salinas, C.
    JOURNAL OF CROHNS & COLITIS, 2014, 8 : S309 - S309
  • [9] Adalimumab As First-Line Anti-TNF Treatment in Pediatric Crohn's Disease
    Martin-de-Carpi, Javier
    Navas-Lopez, Victor
    Navalon-Rubio, Maria
    Llerena-Santa-Cruz, Enrique
    Ortega, David Gil
    Varea-Calderon, Vicente
    Sierra-Salinas, Carlos
    GASTROENTEROLOGY, 2014, 146 (05) : S780 - S780
  • [10] COST-EFFECTIVENESS OF SEQUENCING VEDOLIZUMAB AS FIRST-LINE BIOLOGIC IN ULCERATIVE COLITIS AND CROHN'S DISEASE IN CANADA
    Fischer, A.
    Mac, S.
    Freiman, E.
    Marshall, J.
    Rand, K.
    Ramos-Goni, J. M.
    VALUE IN HEALTH, 2023, 26 (12) : S84 - S84
12345